Tags

Type your tag names separated by a space and hit enter

Moderate Parkinson's disease. Strategies for maximizing treatment.
Postgrad Med. 1996 Jan; 99(1):52-4, 61-3, 67-8, passim.PM

Abstract

Motor fluctuations and dyskinesia often develop in patients with Parkinson's disease after 3 to 5 years of levodopa therapy. Dosage adjustments, addition of a second medication to the drug regimen, and dietary modifications may help maximize response to symptomatic therapy. Given the dramatic variability of symptoms and response to treatment, drug regimens must be individualized according to the patient's needs. In newly diagnosed cases of Parkinson's disease, administration of selegiline hydrochloride (Eldepryl) may slow symptom development and delay the need for levodopa therapy. Many physicians prescribe selegiline initially for its symptomatic and potential neuroprotective benefits.

Authors+Show Affiliations

Struthers Parkinson's Center, Methodist Hospital, St Louis Park, Minnesota, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8539210

Citation

Silverstein, P M.. "Moderate Parkinson's Disease. Strategies for Maximizing Treatment." Postgraduate Medicine, vol. 99, no. 1, 1996, 52-4, 61-3, 67-8, passim.
Silverstein PM. Moderate Parkinson's disease. Strategies for maximizing treatment. Postgrad Med. 1996;99(1):52-4, 61-3, 67-8, passim.
Silverstein, P. M. (1996). Moderate Parkinson's disease. Strategies for maximizing treatment. Postgraduate Medicine, 99(1), 52-4, 61-3, 67-8, passim.
Silverstein PM. Moderate Parkinson's Disease. Strategies for Maximizing Treatment. Postgrad Med. 1996;99(1):52-4, 61-3, 67-8, passim. PubMed PMID: 8539210.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Moderate Parkinson's disease. Strategies for maximizing treatment. A1 - Silverstein,P M, PY - 1996/1/1/pubmed PY - 1996/1/1/medline PY - 1996/1/1/entrez SP - 52-4, 61-3, 67-8, passim JF - Postgraduate medicine JO - Postgrad Med VL - 99 IS - 1 N2 - Motor fluctuations and dyskinesia often develop in patients with Parkinson's disease after 3 to 5 years of levodopa therapy. Dosage adjustments, addition of a second medication to the drug regimen, and dietary modifications may help maximize response to symptomatic therapy. Given the dramatic variability of symptoms and response to treatment, drug regimens must be individualized according to the patient's needs. In newly diagnosed cases of Parkinson's disease, administration of selegiline hydrochloride (Eldepryl) may slow symptom development and delay the need for levodopa therapy. Many physicians prescribe selegiline initially for its symptomatic and potential neuroprotective benefits. SN - 0032-5481 UR - https://www.unboundmedicine.com/medline/citation/8539210/Moderate_Parkinson's_disease__Strategies_for_maximizing_treatment_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.